Use of Docetaxel based Chemotherapy for Castrate Resistant Prostate Cancer at LASUTH Ikeja Lagos Olufunmilade Akin Omisanjo.

Slides:

Advertisements

Similar presentations

PSA in 2010 James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Department of Urology Prostate Cancer Research Program Roswell Park Cancer Institute,

Advertisements

Progress Against Prostate Cancer. 1970–1979 Progress Against Prostate Cancer 1970–1979 Early 1970s: Radioactive ''seeds'' proven effective for prostate.

Research Relevant Evidence Articles: POEM: Patient Oriented Evidence that Matters DOE: Disease Oriented Evidence Problems: Common: conditions encountered.

Clinical Effectiveness Dr. Shahram Yazdani Associate Professor of SBUMS.

ASCO G.U Lawrence H. Einhorn.

Castrate-resistant prostate cancer (CRPC)

Modified Megestrol The Clinical Trials by : Carolina R. Akib

What is the role of free PSA? Total PSA Range 2.5 to 4.0 ng/ml Age Range (Years) %Free PSA=60 (yrs)All Ages

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

Prostate Cancer Int. 洪毓謙. Prostate cancer is the Second leading cause of death from cancer in the United States American male, the lifetime risk of:

M Ravanbod Medical oncologist Bushehr – 11/91 A 50 y/o white man comes for check up and wants to discuss about prostate cancer. Negative family history.

STAMPEDE trial (MRC PR08): Arm J overview

Prostate cancer: To screen or not to screen – To treat or not to treat Dr Oliver Klein – Medical Oncologist.

Drug Treatment of Metastatic Breast Cancer

Interdisciplinary Care and Treatment Involves Us TOO James Kiefert, EdD Chairman, Board of Directors Us TOO International Prostate Cancer Education and.

How should we sequence therapy? Dipartimento Scienze Radiologiche, Oncologiche e Anatomo Patologiche; Oncologia B. “Sapienza” Università di Roma Enrico.

Howard M. Sandler, MD University of Michigan Medical School

Should I have that blood test for Prostate Cancer?

Taxane-pretreated metastatic breast cancer (MBC): investigational agents TTP = median time to disease progression OS = median overall survival.

Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,

Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line human epidermal growth factor receptor.

A Randomized Phase II Study of OGX-011 in Combination with Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Patients.

Low dose chemotherapy with insulin (Insulin Potentiation Therapy) in combination with hormone therapy for treatment of castration resistant prostate cancer.

Hormone Refractory Prostate Cancer A Regulatory Perspective of End Points to Measure Safety and Efficacy of Drugs Hormone Refractory Prostate Cancer Bhupinder.

Phase III studies of Xeloda® in colorectal cancer (CRC)

Immunotherapeutic Approaches in Castration Resistant Prostate Cancer (CRPC) Philip Kantoff, MD Chief, Division of Solid Tumor Oncology Dana-Farber Cancer.

Routine PSA: Evaluating the Evidence Sheldon Greenfield, MD Health Policy Research Institute University of California, Irvine October 23, 2012.

Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.

PSA Shared Care Jim Wood. Background A significant number of men with prostate cancer (CaP) are receiving regular hospital follow up (out- patient visits),

Design of Clinical Trials for Select Patients With a Rising PSA following Primary Therapy Anthony V. D’Amico, MD, PhD Professor of Radiation Oncology Harvard.

Protocols for Advanced Prostate Cancer and/or Local Failure After Radical Prostatectomy Isaac Powell, MD.

Predicting Subsequent Response to Hormone Therapy Following First-line Androgen Deprivation in Advanced Prostate Cancer S. Turner H. Gurney V. Gebski M.

Phase III trial of chemotherapy with or without irinotecan in the front-line treatment of metastatic colorectal cancer in elderly patients. FFCD

A prospective randomized trial

MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for.

. Background Paclitaxel and Irinotecan in Platinum Refractory or Resistant Small Cell Lung Cancer: a Galician Lung Cancer.

Table 1. Characteristics of patients and the results of the log-rank test of prognostic factors Median (range) No. of patients No. of CRPC Median progression.

Inotuzumab Ozogamicin (IO; CMC544), a CD22 Monoclonal Antibody Attached to Calicheamycin, Produces Complete Response (CR) plus Complete Marrow Response.

A Multicentre Phase II Study of Cisplatin (C), Gemcitabine (G), and Bevacizumab (B) as First-Line Chemotherapy for Metastatic.

Cabozantinib (XL184) in metastatic castration- resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation.

Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.

1 A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine with Celecoxib.

Agency Review of sNDA SE-006 DOXIL for Ovarian Cancer Division of Oncology Drug Products Office of Drug Evaluation 1 Center for Drug Evaluation.

The Cost of Living Stephen Hall. Pharmaceutical Sales (Billions)

Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.

PHASE II RANDOMIZED STUDY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB PLUS DOCETAXEL IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 – POSITIVE.

Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.

Prof. Jae Heon, Jeong/R2 Cheol Hyun, Lee J of Clinical oncology, Vol 31 Number 4, Feb.1, 2013.

Abiraterone Changes in Landscape of Advanced Prostate Cancer

European Urology Focus

CCO Independent Conference Coverage

Volume 155, Issue 3, Pages (March 1996)

Updates in Prostate Cancer Prepared for GP master class – Sept 2016

PHASE I/II STUDY OF PEGYLATED LIPOSOMAL DOXORUCIN (PLD) AND GEMCITABINE (GEM) IN RECURRENT PLATIN RESISTANT OVARIAN CANCER (OC). A Study of the VWOG.

Management of metastatic castration-resistant prostate cancer: Insights from urology experts in Thailand Bannakij Lojanapiwat, Choosak Pripatnanont,

Metastatic Castration-Resistant Prostate Cancer: Two Case Reports of Dramatic Response with Abiraterone Acetate in Patients Heavily Pretreated with Chemotherapy.

David Lorente, Karim Fizazi, Christopher Sweeney, Johann S. de Bono

Volume 68, Issue 6, Pages e129-e131 (December 2015)

Jones SE et al. SABCS 2009;Abstract 5082.

Moving Prostate Cancer Care Forward: Putting Lessons From New Orleans and Chicago Into Practice.

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Volume 66, Issue 3, Pages (September 2014)

Reviewer: Dr. Sunil Verma Date posted: December 12th, 2011

Current Guidelines in the treatment of Prostate Cancer: what is most appropriate for Nigerian patients? Dr Emmanuel Ajibola Jeje BSc. M. B. Ch.B; FMCS;

EARLY AND LATE COMPLICATIONS OF PROSTATE LOW DOSE BRACHYTHERAPY

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

What's New in Prostate Cancer: Highlights from Urologic and Oncologic Congresses in 2006 Michel Soulié, Nicolas Mottet, Laurent Salomon, Jacques Irani,

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

ONCOLOGYEDUCATION.COM ARTICLE SUMMARIES

Presentation transcript:

Use of Docetaxel based Chemotherapy for Castrate Resistant Prostate Cancer at LASUTH Ikeja Lagos Olufunmilade Akin Omisanjo

Background Burden of CAP No widespread screening in Nigeria Late presentation Inevitable progression to CRPC

Background II Challenges with CRPC in Nigeria -different criteria - available treatment options - costs - “physician apathy “ Dearth of Medical/Radiation Oncologists Limited documented experience

Objectives To describe our initial experience with the use of Docetaxel based Chemotherapy in the treatment of CRPC

Materials and Method Patients with CRPC - Steady rise in PSA - Post Ochidectomy - Antiandrogen Treatment - Antiandrogen Withdrawal & Substitution - Testosterone levels in 5 patients - Karnofsky Index 15 month period ( Jan 2013 – March 2014 )

Results 8 patients Mean age : 70.4years ( 65 – 76yrs) Mean PSA pre-commencement of Chemotherapy : 553.1ng/ml ( )

Results II 3 weekly dose : 75mg/m patients Weekly dose : 30mg/m patients Preparation - FBC - E&U,Cr - LFTs - ECG

Results III Drug administration by urologists in all cases 7 patients completed chemotherapy - 5 patients : 6 courses - 2 patients : 10 courses Discontinued in 1 patient

Results III Mean drop in PSA : 67.9% Mean follow up period : 10months ( 4- 18mths)

Results IV Clinical Improvement - analgesia requirements - paraplegia Mortality - 1 cancer related death - 1 non-cancer related death 6 alive - 4 patients up to 12months

Discussion Very high PSA Acceptable Tolerability - Good performance ? Cost effectiveness Study : not about efficacy

Limitations/Recommendations Limited patients Need for multi-centre involvement Chemotherapy for CRPC is possible even in a very busy urology practice More involvement by urologists

THANK YOU